Investigation into Sanara MedTech for Alleged Securities Fraud
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SMTI?
Source: Globenewswire
- Operational Halt Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus program to reallocate resources to its core surgical business, resulting in a net loss of $31.2 million, indicating significant financial strain during the business adjustment.
- Asset Impairment Loss: Following the cessation of the THP program, Sanara reported a noncash asset impairment charge of $26.5 million, which directly impacted the company's financial health and highlighted its vulnerability in market competition.
- Stock Price Plunge: On November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 per share, severely undermining investor confidence and potentially complicating future financing efforts.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Sanara and its executives engaged in securities fraud or other unlawful business practices, which could further affect the company's reputation and shareholder interests, increasing future legal risks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SMTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SMTI
Wall Street analysts forecast SMTI stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 18.930
Low
36.00
Averages
36.00
High
36.00
Current: 18.930
Low
36.00
Averages
36.00
High
36.00
About SMTI
Sanara Medtech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets. Its Sanara Surgical segment primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. Its Tissue Health Plus segment is focused on value-based wound care services. It markets and distributes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft and FORTIFY FLOWABLE Extracellular Matrix as well as a portfolio of advanced biologic products focusing on ACTIGEN Verified Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, BiFORM Bioactive Moldable Matrix, TEXAGEN Amniotic Membrane Allograft, and BIASURGE Advanced Surgical Solution to the surgical market. BIAKOS Antimicrobial Wound Gel and others are the products sold in the wound care market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigation into Sanara MedTech for Alleged Securities Fraud
- Operational Halt Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus program to reallocate resources to its core surgical business, resulting in a net loss of $31.2 million, indicating significant financial strain during the business adjustment.
- Asset Impairment Loss: Following the cessation of the THP program, Sanara reported a noncash asset impairment charge of $26.5 million, which directly impacted the company's financial health and highlighted its vulnerability in market competition.
- Stock Price Plunge: On November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 per share, severely undermining investor confidence and potentially complicating future financing efforts.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Sanara and its executives engaged in securities fraud or other unlawful business practices, which could further affect the company's reputation and shareholder interests, increasing future legal risks.
See More
Sanara MedTech to Report Q1 2026 Financial Results
- Earnings Release Schedule: Sanara MedTech is set to announce its Q1 2026 financial results on May 12, 2026, before U.S. market opening, reflecting the company's ongoing development and market performance in the medical technology sector.
- Conference Call Details: On the same day, the company will host a conference call at 8:00 a.m. Eastern Time to discuss the quarterly results ending March 31, 2026, with a Q&A session to enhance investor engagement.
- Replay Service Availability: Following the call, investors can access a telephonic replay by dialing 877-481-4010 (international: 919-882-2331), available until May 26, 2026, ensuring information accessibility.
- Product Market Positioning: Sanara focuses on developing and commercializing innovative technologies in the surgical market, primarily selling products like CellerateRX® and BIASURGE®, aimed at improving clinical outcomes and reducing healthcare costs, thereby strengthening its competitive position in North America.
See More
Sanara MedTech Reports Record $103.1M Revenue in 2025
- Significant Revenue Growth: Sanara MedTech achieved a record $103.1 million in net revenue for 2025, marking a 19% year-over-year increase, which underscores the strength of its hybrid commercial model and is expected to further enhance market share.
- Distributor Network Expansion: The company expanded its network to over 450 independent distributor partners by year-end 2025, up from more than 350 in 2024, successfully penetrating over 1,450 healthcare facilities, thereby increasing market penetration and customer base.
- Strategic Focus Transformation: The completion of the wind-down of the Tissue Health Plus (THP) segment allows the company to concentrate on the surgical market, with core products like CellerateRx Surgical and BIASURGE, which are expected to lay a solid foundation for future growth.
- Optimistic Future Outlook: Management reaffirmed full-year 2026 net revenue guidance between $116 million and $121 million, representing a growth of 13% to 17%, and plans to invest in expanding the sales team and R&D to support sustainable growth.
See More
Sanara MedTech Q4 Earnings Report Analysis
- Earnings Highlights: Sanara MedTech reported a Q4 GAAP EPS of -$0.19, yet achieved revenue of $27.5 million, reflecting a 4.6% year-over-year growth, demonstrating the company's resilience in challenging conditions.
- Future Outlook: The company anticipates full-year 2026 net revenue to range from $116 million to $121 million, representing a growth of approximately 13% to 17% compared to $103.1 million in 2025, indicating management's confidence in future growth.
- Revenue Expectations: Sanara MedTech expects Q4 revenue to be between $27.2 million and $27.7 million, aligning with actual revenue figures, which reflects the company's stable performance in the market.
- Market Reaction: Despite challenges, Sanara MedTech's financial performance and future guidance may attract investor interest, potentially supporting its stock price performance to some extent.
See More
SANARA MEDTECH INC - CONFIRMS FY2026 NET REVENUE PROJECTION OF $116-$121 MILLION, EXPECTING 13%-17% GROWTH
- Revenue Guidance: Sanara MedTech has provided revenue guidance for FY 2026, estimating between $116 million and $121 million.
- Growth Projection: The company anticipates a growth rate of 13% to 17% for the upcoming fiscal year.
See More
SANARA MEDTECH INC REPORTS 5% RISE IN Q4 2025 NET REVENUE TO $27.5 MILLION
- Revenue Growth: Sanara MedTech's revenue for Q4 2025 has increased by 5%, reaching $27.5 million.
- Financial Performance: The increase in revenue indicates a positive trend in the company's financial performance during this period.
See More
Investigation into Sanara MedTech for Alleged Securities Fraud
- Operational Halt Impact: On November 11, 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus program to reallocate resources to its core surgical business, resulting in a net loss of $31.2 million, indicating significant financial strain during the business adjustment.
- Asset Impairment Loss: Following the cessation of the THP program, Sanara reported a noncash asset impairment charge of $26.5 million, which directly impacted the company's financial health and highlighted its vulnerability in market competition.
- Stock Price Plunge: On November 12, 2025, Sanara's stock price fell by $6.93, or 24.7%, closing at $21.11 per share, severely undermining investor confidence and potentially complicating future financing efforts.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Sanara and its executives engaged in securities fraud or other unlawful business practices, which could further affect the company's reputation and shareholder interests, increasing future legal risks.
See More
Sanara MedTech to Report Q1 2026 Financial Results
- Earnings Release Schedule: Sanara MedTech is set to announce its Q1 2026 financial results on May 12, 2026, before U.S. market opening, reflecting the company's ongoing development and market performance in the medical technology sector.
- Conference Call Details: On the same day, the company will host a conference call at 8:00 a.m. Eastern Time to discuss the quarterly results ending March 31, 2026, with a Q&A session to enhance investor engagement.
- Replay Service Availability: Following the call, investors can access a telephonic replay by dialing 877-481-4010 (international: 919-882-2331), available until May 26, 2026, ensuring information accessibility.
- Product Market Positioning: Sanara focuses on developing and commercializing innovative technologies in the surgical market, primarily selling products like CellerateRX® and BIASURGE®, aimed at improving clinical outcomes and reducing healthcare costs, thereby strengthening its competitive position in North America.
See More
Sanara MedTech Reports Record $103.1M Revenue in 2025
- Significant Revenue Growth: Sanara MedTech achieved a record $103.1 million in net revenue for 2025, marking a 19% year-over-year increase, which underscores the strength of its hybrid commercial model and is expected to further enhance market share.
- Distributor Network Expansion: The company expanded its network to over 450 independent distributor partners by year-end 2025, up from more than 350 in 2024, successfully penetrating over 1,450 healthcare facilities, thereby increasing market penetration and customer base.
- Strategic Focus Transformation: The completion of the wind-down of the Tissue Health Plus (THP) segment allows the company to concentrate on the surgical market, with core products like CellerateRx Surgical and BIASURGE, which are expected to lay a solid foundation for future growth.
- Optimistic Future Outlook: Management reaffirmed full-year 2026 net revenue guidance between $116 million and $121 million, representing a growth of 13% to 17%, and plans to invest in expanding the sales team and R&D to support sustainable growth.
See More
Sanara MedTech Q4 Earnings Report Analysis
- Earnings Highlights: Sanara MedTech reported a Q4 GAAP EPS of -$0.19, yet achieved revenue of $27.5 million, reflecting a 4.6% year-over-year growth, demonstrating the company's resilience in challenging conditions.
- Future Outlook: The company anticipates full-year 2026 net revenue to range from $116 million to $121 million, representing a growth of approximately 13% to 17% compared to $103.1 million in 2025, indicating management's confidence in future growth.
- Revenue Expectations: Sanara MedTech expects Q4 revenue to be between $27.2 million and $27.7 million, aligning with actual revenue figures, which reflects the company's stable performance in the market.
- Market Reaction: Despite challenges, Sanara MedTech's financial performance and future guidance may attract investor interest, potentially supporting its stock price performance to some extent.
See More
SANARA MEDTECH INC - CONFIRMS FY2026 NET REVENUE PROJECTION OF $116-$121 MILLION, EXPECTING 13%-17% GROWTH
- Revenue Guidance: Sanara MedTech has provided revenue guidance for FY 2026, estimating between $116 million and $121 million.
- Growth Projection: The company anticipates a growth rate of 13% to 17% for the upcoming fiscal year.
See More
SANARA MEDTECH INC REPORTS 5% RISE IN Q4 2025 NET REVENUE TO $27.5 MILLION
- Revenue Growth: Sanara MedTech's revenue for Q4 2025 has increased by 5%, reaching $27.5 million.
- Financial Performance: The increase in revenue indicates a positive trend in the company's financial performance during this period.
See More
